ArriVent BioPharma (AVBP) EBITDA (2023 - 2026)

ArriVent BioPharma has disclosed EBITDA across 4 years of filings, most recently posting -$43.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$43.6 million, up 32.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$145.5 million (down 14.14% YoY), and the FY2025 annual result was -$166.1 million, down 105.81% from the prior year.
• EBITDA came in at -$43.6 million for Q1 2026 at ArriVent BioPharma, down from -$35.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$12.2 million in Q1 2023 to a low of -$64.2 million in Q1 2025.
• The 4-year median for EBITDA is -$22.6 million (2023), against an average of -$28.1 million.
• Across the five-year window, EBITDA slumped 268.57% in 2025 and jumped 32.07% in 2026, its largest moves.
• ArriVent BioPharma's EBITDA stood at -$23.1 million in 2023, then rose by 9.84% to -$20.8 million in 2024, then slumped by 71.45% to -$35.7 million in 2025, then slipped by 22.01% to -$43.6 million in 2026.
• The last three EBITDA figures came in at -$43.6 million (Q1 2026), -$35.7 million (Q4 2025), and -$34.8 million (Q3 2025), per Business Quant data.